WO2011084714A3 - STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF - Google Patents

STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF Download PDF

Info

Publication number
WO2011084714A3
WO2011084714A3 PCT/US2010/061164 US2010061164W WO2011084714A3 WO 2011084714 A3 WO2011084714 A3 WO 2011084714A3 US 2010061164 W US2010061164 W US 2010061164W WO 2011084714 A3 WO2011084714 A3 WO 2011084714A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
alpha
scfv molecules
binding molecules
tweak
Prior art date
Application number
PCT/US2010/061164
Other languages
French (fr)
Other versions
WO2011084714A2 (en
Inventor
Brian Robert Miller
Jennifer Michaelson
Stephen Demarest
Dikran Aivazian
Alexey Alexandrovich Lugovskoy
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of WO2011084714A2 publication Critical patent/WO2011084714A2/en
Publication of WO2011084714A3 publication Critical patent/WO2011084714A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The instant invention is based, at least in part on the finding that binding molecules which simultaneously bind to multiple epitopes within TNF-alpha result in improved TNFR-1 and/or TNFR-2 blocking capabilities when compared to binding molecules that bind to a single TNF-alpha epitope. The instant invention provides compositions that bind to multiple epitopes of TNF-alpha, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize TNF-alpha signaling are also provided.
PCT/US2010/061164 2009-12-17 2010-12-17 STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF WO2011084714A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28769109P 2009-12-17 2009-12-17
US61/287,691 2009-12-17
US29682910P 2010-01-20 2010-01-20
US61/296,829 2010-01-20

Publications (2)

Publication Number Publication Date
WO2011084714A2 WO2011084714A2 (en) 2011-07-14
WO2011084714A3 true WO2011084714A3 (en) 2011-10-27

Family

ID=44306075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/061164 WO2011084714A2 (en) 2009-12-17 2010-12-17 STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF

Country Status (1)

Country Link
WO (1) WO2011084714A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
MX2010011955A (en) 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
CA2803392A1 (en) * 2010-06-24 2011-12-29 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN103260639A (en) 2010-08-26 2013-08-21 Abbvie公司 Dual variable domain immunoglobulins and uses thereof
US20140255405A1 (en) * 2011-05-27 2014-09-11 Dutalys Removal of Monomeric Targets
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
JP6220344B2 (en) 2011-11-29 2017-10-25 プロクララ バイオサイエンシーズ， インコーポレイテッド Use of bacteriophage P3 as an amyloid binder
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
KR102101258B1 (en) 2012-10-02 2020-04-16 프로클라라 바이오사이언시즈, 인크. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
KR20210111353A (en) 2012-11-01 2021-09-10 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
US9988444B2 (en) * 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
GB201315788D0 (en) * 2013-09-05 2013-10-23 Univ London Queen Mary Molecule
WO2015051234A2 (en) * 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
EP3062818B1 (en) * 2013-11-01 2019-09-11 IBC Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
MX2016012479A (en) 2014-03-26 2017-05-23 Cell Medica Switzerland Ag Binding members to tnf alpha.
US10071139B2 (en) 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
JP6730988B2 (en) 2014-12-03 2020-07-29 プロクララ バイオサイエンシーズ， インコーポレイテッド Polypeptides containing modified bacteriophage g3p amino acid sequences lacking glycosylation signals
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
DK3377618T3 (en) 2015-11-19 2020-12-21 Univ Pennsylvania Buffers for stabilizing lentivirus preparations
CN109789224A (en) * 2016-05-05 2019-05-21 宾夕法尼亚大学理事会 Target the DNA monoclonal antibody of IL-6 and CD126
AU2018366122A1 (en) * 2017-11-10 2020-04-23 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof
SG11202012706PA (en) 2018-06-21 2021-01-28 Yumanity Therapeutics Inc Compositions and methods for the treatment and prevention of neurological disorders
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN112843225B (en) * 2021-01-19 2023-05-26 贵州省畜牧兽医研究所 Riemerella anatipestifer DNA vaccine based on RA OmpA gene, and preparation method and identification method thereof
TWI821881B (en) * 2021-01-29 2023-11-11 醫研生物科技有限公司 Tumor necrosis factor alpha recombinant antibody and use thereof
CA3207134A1 (en) * 2021-02-19 2022-08-25 Jeffrey A. Ledbetter Dnase fusion polypeptides and related compositions and methods
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202104A1 (en) * 2002-07-19 2007-08-30 Abbott Laboratories S.A. Treatment of spondyloarthropathies using TNFalpha inhibitors
US20090269357A1 (en) * 2008-04-23 2009-10-29 Yaohuang Ke ANTI-TNFalpha ANTIBODY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202104A1 (en) * 2002-07-19 2007-08-30 Abbott Laboratories S.A. Treatment of spondyloarthropathies using TNFalpha inhibitors
US20090269357A1 (en) * 2008-04-23 2009-10-29 Yaohuang Ke ANTI-TNFalpha ANTIBODY

Also Published As

Publication number Publication date
WO2011084714A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2011084714A3 (en) STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
WO2009032782A3 (en) Compositions that bind multiple epitopes of igf-1r
PE20240218A1 (en) AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5
MX2020010382A (en) Bispecific antibodies specific for pd1 and tim3.
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
PH12019501464A1 (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
WO2012125569A3 (en) Anti-cd40 antibodies and uses thereof
RU2017128882A (en) ANTIBODIES TO BIOTIN AND WAYS OF THEIR APPLICATION
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
WO2013037484A8 (en) ANTI-αβTCR ANTIBODY
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
NZ766356A (en) Anti-pd-1 antibodies
JP2013198490A5 (en)
WO2015127136A3 (en) Ebola monoclonal antibodies
JP2013538057A5 (en)
WO2013119966A3 (en) Single-chain antibodies and other heteromultimers
IL258215B (en) Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2011051327A3 (en) Small antibody-like single chain proteins
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ602020A (en) Anti-cd40 antibodies
WO2011130377A3 (en) Amyloid-beta binding proteins
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10842667

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10842667

Country of ref document: EP

Kind code of ref document: A2